Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapeutics for liver diseases and viral infections. The company's pipeline focuses on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. Its lead candidate, pevifoscorvir sodium, is a capsid assembly modulator (CAM-E) in Phase 2 trials for chronic HBV. ALG-055009 is a thyroid hormone receptor beta agonist for MASH and obesity, and ALG-097558 is a small molecule coronavirus 3CL protease inhibitor for coronavirus infections. The company also maintains an antisense oligonucleotide (ASO) platform, including ALG-170675 for HBV, developed in partnership with Xiamen Amoytop Biotech Co., Ltd. Aligos targets patients with unmet medical needs in hepatology and virology, with clinical studies conducted in the United States, Europe, and China.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage aligos.com
Sector Healthcare IR page investor.aligos.com
Tags
hepatology, virology, chronic hepatitis b, mash, obesity, coronavirus, capsid assembly modulators, antisense oligonucleotides, protease inhibitors, thyroid hormone receptor agonists, pevifoscorvir sodium, ALG-000184, ALG-055009, ALG-097558, ALG-170675, Xiamen Amoytop Biotech Co. Ltd., Amoytop
Press page —

Metrics

Valuation  
Market cap $ 35.179M
Market cap (USD) $ 35.179M
P/E -0.87
PEG —
P/BV 3.11
P/S 16.09
P/OCF -0.51
P/FCF -0.42
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.2%
ROI -68.6%
ROIC -187.2%
Profit margin -1,106.7%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 52
Quality score -78.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 2.186M 3.611M 6.191M 0 0 0 —
Net profit -24.193M -131.211M -87.679M -96.046M -128.332M -108.543M -52.264M
Free cash flow -82.94M -80.873M -79.016M -80.332M -116.554M -76.327M -49.553M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 9.32 39.84 0.66 0.95 11.87 27.65 —
Price performance 12m -0.77 59 -0.3 -0.92 -0.57 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 14.3M 13M 14.5M 12.6M 11.1M 8.38M 5.25M
Cash and deposits (USD) 24.5M 69.6M 220M 187M 81.3M 136M 37M 18.3M
Right-of-use assets (USD) — 7.57M 6.9M 8.79M 7.7M 6.56M 4.96M 3.09M
Cash flow detail
Operating cash flow (USD) — -46.8M -74.3M -116M -79.4M -79M -80.7M -82.5M
Purchases of property, plant and equipment (USD) — -2.79M -2.06M -892,000 -943,000 -19,000 -130,000 —
Change in payables (cash effect) (USD) — 385,000 -130,000 -313,000 1.72M -2.22M 54,000 1.41M
Interest paid (cash effect) (USD) — -6,000 — — — — — —
Income taxes paid (cash effect) (USD) — -1,000 — — — — — -315,000
Share-based compensation (USD) — 752,000 2.98M 13.5M 14.7M 12.7M 8.45M 5.04M
Free cash flow (OCF - PPE - intangibles) (USD) — -49.6M -76.3M -117M -80.3M -79M -80.9M —
Income detail
Research and development expense (USD) — 44M 79.9M 104M 85.1M 73M 70.3M 69.5M
↳ 5y CAGR +9.8% -2.8%
Total comprehensive income (USD) — -52.4M -109M -128M -96.1M -87.5M -131M -24.2M
Comprehensive income to owners (USD) — -52.4M -109M -128M -96.1M -87.5M -131M -24.2M
Reported Nov 25, 2020 Mar 23, 2021 Mar 23, 2021 Mar 10, 2022 Mar 9, 2023 Mar 12, 2024 Mar 10, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.

“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop.

Oct 5, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Abstract #: 4139 **Title:**Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT **Session:**Hepatitis B ("4001-4193"); Poster of Distinction

Abstract #: 4142 **Title:**Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT **Session:**Hepatitis B ("4001-4193")

Abstract #: 4158 **Title:**Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro Presenter: Andreas Jekle, PhD Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT **Session:**Hepatitis B ("4001-4193")

ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection

Abstract #: 4156 **Title:**The potentially best-in-class HBV ASO ALG-170675 demonstrates a favourable preclinical profile: efficacy in an AAV-HBV mouse model, pharmacokinetics and safety in mouse and monkey Presenter: Jin Hong, PhD Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT **Session:**Hepatitis B ("4001-4193")

Preclinical

Abstract #: 3224 **Title:**Potent Inhibition of Hepatitis Delta Virus Replication by the Antisense Oligonucleotide ALG-215007 Presenter: Kellan Passow, PhD Date/Time: November 7, 2026 at 1:00pm – 2:00pm MT **Session:**Hepatitis - Other Infections ("3195-3246")

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.

On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated as of June 21, 2018, by and between the Landlord and the Company (as amended, the “Lease”), relating to office space located at One Corporate Drive, 2nd Floor, South San Francisco, CA 94080, which serves as the Company’s headquarters. The First Amendment extends the term of the Lease from March 31, 2027 to March 31, 2034. The First Amendment provides that the base monthly rent, per rentable square foot of the leased space, will be $4.650 from April 1, 2027 to March 31, 2028, $4.813 from April 1, 2028 to March 31, 2029, $4.981 from April 1, 2029 to March 31, 2030, $5.156 from April 1, 2030 to March 31, 2031, $5.336 from April 1, 2031 to March 31, 2032, $5.523 from April 1, 2032 to March 31, 2033, and $5.716 from April 1, 2033 to March 31, 2034, and that the Company will be obligated to pay a specified percentage of certain expenses paid by the Landlord.

Prompts

Aligos Therapeutics, Inc. (ticker ALGS), listed in United States.

ETFs Holding Aligos Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
DFSU 0.00% 1,149 $ 2,275.02 Nov 12, 2026
DXUV 0.00% 2,093 $ 4,144.14 Nov 12, 2026
DFAS 0.00% 6,383 $ 12.638K Nov 12, 2026
DFAC 0.00% 1,855 $ 3,672.90 Nov 12, 2026
AVSC 0.00% 1,427 $ 2,368.82 Nov 16, 2026